Diflucortolone valerate (Nerisona)

PreclinicalSmall molecule

Diflucortolone valerate (Nerisona) is one of 41 small molecule programs targeting Cleft Palate. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cleft PalateActive, not recruiting

Atopic DermatitisActive, not recruiting

Cleft PalatePreclinical

Active, not recruiting

Atopic DermatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

11 2

Daliresp

AstraZeneca

Phase 3

4 3

Cytosar

Teva

Phase 3

1 4

Nereus

VVanda Pharmaceuticals

Phase 3

3 5

Celestone

SSchering-Plough

Phase 3

2 6

Ciclosporin

Novartis

Phase 3

4 7

Calcineurin Inhibitors

Sanofi

Phase 3

1 8

Bepreve

BBausch Health Americas, Inc.

Phase 3

1 9

EBGLYSS

Cibinqo

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cleft Palate1 trial

A Study to Learn More About the Relationship Between the Development of a Gap in the Upper Lip (Cleft Lip) or in the Roof of the Mouth (Cleft Palate) in Newborns and the Use of Glucocorticoids by the Mother During Pregnancy: a Meta-analysis

Completed· LEO Pharma logo

LEO Pharma··NCT03788863·99,999 enrolled

Atopic Dermatitis1 trial

An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids

Completed· LEO Pharma logo

LEO Pharma··NCT02627989·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Diflucortolone valerate (Nerisona). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diflucortolone valerate (Nerisona) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diflucortolone valerate (Nerisona). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LEO Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LEO Pharma

Diflucortolone valerate (Nerisona)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cleft Palate1 trial

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News